Induction of apoptosis and cell cycle arrest in glioma cells by GL331 (a topoisomerase II inhibitor)

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 4203-4208

  Chen, Yun ^a   Su, Yen Hao ^b   Wang, Chih Hsien ^b   Wu, Jiann Ming ^a   Chen, Jin Cherng ^c   Tseng, Sheng Hong ^b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Cell cycle; GL331; Glioma; Topoisomerase II inhibitor

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; GL 331; GYRASE INHIBITOR; PROTEIN 14 3 3SIGMA; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE PHASE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; GLIOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

14-3-3 PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; ETOPOSIDE; G2 PHASE; GLIOMA; RATS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 27944480351     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Salcman M: Epidemiology and factors affecting survival. In: Malignant Cerebral Glioma. Apuzzo MLJ (ed.). American Association of Neurological Surgeons, Illinois, pp. 95-109, 1990.
2. Weller M, Winter S, Schmidt C, Esser P, Fontana A, Dichgans J and Groscurth P: Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone. Int J Cancer 73: 707-714, 1997.
3. Berger JM, Gamblin SJ, Harrison SC and Wang JC: Structure and mechanism of DNA topoisomerase II. Nature 379: 225-232, 1996.
4. Giocanti N, Hennequin C, Balosso J, Mahler M and Favaudon V: DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res 53: 2105-2111, 1993.
5. Taniguchi K, Wakabayashi T, Yoshida T, Mizuno M, Yoshikawa K, Kikuchi A, Nakashima N and Yoshida J: Immunohistochemical staining of DNA topoisomerase IIα in human gliomas. J Neurosurg 91: 477-482, 1999.
6. Burris HA, Rothenberg ML, Kuhn JG and von Hoff DD: Clinical trials with topoisomerase I inhibitors. Semin Oncol 19: 663-669, 1992.
7. Haddock MG, Ames MM and Bonner JA: Assessing the interaction of irradiation with etoposide or idarubicin. Mayo Clin Proc 70: 1053-1060, 1995.
8. Lee CC and Huang TS: A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage. Pharmaceut Res 18: 846-851, 2001.
9. Beauchesne P, Soler C, Rusch P, Fotso M J, Duthel R, Schmitt T and Brunon J: Phase II study of a radiotherapy/etoposide combination for patients with newly malignant gliomas. Cancer Chemother Pharmacol 44: 210-216, 1999.
10. Whang-Peng J and Huang TS: New trials of GL331, a novel topoisomerase II inhibitor, in treatment of solid tumors. J Intern Med Taiwan 8: 6-11, 1997.
11. Liu JM, Chen LT, Chao Y, Li AF, Wu CW, Liu TS, Shiah HS, Chang JY, Chen JD, Wu HW, Lin WC, Lan C and Whang-Peng J: Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients. Cancer Chemother Pharmacol 49: 425-428, 2002.
12. Huang TS, Lee CC, Chao Y, Shu CH, Chen LT, Chen LL, Chen MH, Yuan CC and Whang-Peng J: A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharmaceut Res 16: 997-1002, 1999.
13. Huang TS, Shu CH, Shih YL, Huang HC, Su YC, Chao Y, Yang WK and Whang-Peng J: Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide. Cancer Lett 110: 77-85, 1996.
14. Huang TS, Shu CH, Yang WK and Whang-Peng J: Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331-induced apoptosis. Cancer Res 57: 2974-2978, 1997.
15. Chang H, Shyu KG, Lee CC, Tsai SC, Wang BW, Lee YH and Lin S: GL331 inhibits HIF-1 alpha expression in a lung cancer model. Biochem Biophys Res Commun 302: 95-100, 2003.
16. Beauchesne P, Bertrand S, N'guyen MJ, Christianson T, Dore JF, Mornex F and Bonner JA: Etoposide sensitivity of radioresistant human glioma cell lines. Cancer Chemother Pharmacol 41: 93-97, 1998.
17. Minehan KJ and Bonner JA: The interaction of etoposide with radiation: variation in cytotoxicity with the sequence of the treatment. Life Sci 53: PL237-242, 1993.
18. Shigematsu N, Kawata T, Ihara N, Kawaguchi O, Kutsuki S, Ishibashi R, Kubo A and Ito H: Effect of combined treatment with radiation and low dose etoposide on cell survival. Anticancer Res 21: 325-328, 2001.
19. Benda P, Lichtbody J, Sato G, Levine L and Sweet WH: Differentiated rat glial cell strain in tissue structure. Science 161: 370-371, 1968.
20. Benda P, Someda K, Messer J and Sweet WH: Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. J Neurosurg 34: 310-323, 1971.
21. Huang TS, Shu CH., Lee CC, Chen LT and Whang-Peng J: In vitro evaluation of GL331's cancer cell killing and apoptosis-inducing activity in combination with other chemotherapeutic agents. Apoptosis 5: 79-85, 2000.
22. Kuo ML, Shen SC, Yang CH, Chuang SE, Cheng AL and Huang TS: Bcl-2 prevents topoisomerase II inhibitor GL-331-induced apoptosis is mediated by down-regulation of poly (ADP-ribose) polymerase activity. Oncogene 17: 2225-2234, 1998.
23. Qiu XB, Schonthal AH and Cadenas E: Anticancer quinones induce pRb-preventable G2/M cell cycle arrest and apoptosis. Free Radical Biol Med 24: 848-854, 1998.
24. cdc2 kinase activity. Exp Cell Res 242: 381-390, 1998.
25. Chan TA, Hermeking H, Lengauer C, Kinzler KW and Vogelstein B: 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616-620, 1999.
26. kip1, and Cdc25C expression. Biochem Pharmacol 6: 979-989, 2001.
27. King RW, Jackson PK and Kirschner MW: Mitosis in transition. Cell 79: 563-571, 1994.
28. Nurse P: Ordering S phase and M phase in the cell cycle. Cell 79: 547-550, 1994.
29. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW and Vogelstein B: 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3-11, 1997.